• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

Jerini AG

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact
jerini

Jerini AG

Exit: 2008
Visit Website
  • Germany
  • Bradikinin B2 receptor based drugs for angioedema and severe burn, drugs for ophthalmic disease indications
  • Investment Period: 7 years
  • 2005 IPO on the Frankfurt Stock Exchange
  • 2008 Strategic Acquisition by Shire Limited

TVM Capital Partner Hubert Birner served on the Supervisory Board and was instrumental in M&A negotiation prior to the acquisition. He served as Vice Chairman of the Board throughout all the years of investment and led the company through several challenging situations include a senior management change over.

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact